| 05/16 | C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 05/16 | C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluat.. | CI |
| 05/16 | C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug | MT |
| 05/16 | C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CF.. | GL |
| 05/09 | HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy R.. | MT |
| 05/05 | C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and .. | AQ |
| 05/05 | C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20.. | CI |
| 05/05 | C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highli.. | GL |
| 04/28 | Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Ris.. | MT |
| 04/18 | UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating | MT |
| 04/12 | NORTH AMERICAN MORNING BRIEFING : Stocks Waver, -3- | DJ |
| 04/11 | AACR PRESENTATION : Preclinical Evaluation of CFT1946 | PU |
| 04/11 | Top Midday Decliners | MT |
| 04/11 | C4 Therapeutics Shares Drop After BofA Securities Downgrade | MT |
| 04/11 | AACR PRESENTATION : The Discovery and Characterization of CFT7455 | PU |
| 04/11 | SVB Leerink Adjusts C4 Therapeutics Price Target to $25 From $40, Maintains Outperform .. | MT |
| 04/11 | Stifel Adjusts C4 Therapeutics' Price Target to $15 From $28, Reiterates Hold Rating | MT |
| 04/11 | BMO Capital Adjusts C4 Therapeutics' Price Target to $20 From $57, Keeps Outperform Rat.. | MT |
| 04/11 | BofA Securities Cuts C4 Therapeutics to Neutral From Buy, Price Target to $15 From $46 | MT |
| 04/10 | AACR PRESENTATION : The Discovery and Characterization of CFT8634 | PU |
| 04/08 | C4 Therapeutics Reports CFT7455 Clinical Trial Data -- Stock Sinks | MT |
| 04/08 | TRANSCRIPT : C4 Therapeutics, Inc. - Special Call | CI |
| 04/08 | C4 THERAPEUTICS : Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical T.. | PU |
| 04/08 | C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 04/08 | AACR POSTER PRESENTATION : CFT7455 Phase 1/2 Cohort A | PU |
| 04/08 | C4 THERAPEUTICS : Corporate Presentation – April 2022 | PU |
| 04/08 | C4 THERAPEUTICS : CFT7455 Phase 1/2 Cohort A Data Investor Call | PU |
| 04/08 | C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical .. | AQ |
| 04/08 | C4 Therapeutics, Inc. Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Cli.. | CI |
| 03/16 | C4 THERAPEUTICS : Appoints Utpal Koppikar to Board of Directors - Form 8-K | PU |
| 03/16 | C4 THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosur.. | AQ |
| 03/16 | C4 Therapeutics, Inc. Announces Resignation of Elena Prokupets as Director and Member o.. | CI |
| 03/16 | C4 Therapeutics Appoints Utpal Koppikar to Board of Directors | GL |
| 03/16 | C4 Therapeutics Appoints Utpal Koppikar to Board of Directors and as Chair of the Audit.. | CI |
| 03/10 | JPMorgan Starts C4 Therapeutics at Overweight With $43 Price Target | MT |
| 03/09 | C4 Therapeutics Shares Climb 17% on FDA Drug Designation | DJ |
| 03/09 | C4 Therapeutics Says FDA Grants Orphan Drug Designation for Soft Tissue Cancer Drug | MT |
| 03/09 | C4 THERAPEUTICS : Cowen Healthcare Conference Presentation | PU |
| 03/09 | C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of .. | AQ |
| 03/09 | C4 Therapeutics Gets Orphan Drug Designation for Sarcoma Treatment | DJ |
| 03/08 | C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annua.. | GL |
| 02/25 | Stifel Nicolaus Adjusts Price Target for C4 Therapeutics to $28 From $44, Maintains Hol.. | MT |
| 02/24 | C4 Therapeutics Full Year 2021 Net Loss Per Share Narrows, Revenue Rises | MT |
| 02/24 | C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and .. | AQ |
| 02/24 | C4 THERAPEUTICS : Reports Full Year 2021 Financial Results and Recent Business Highlights .. | PU |
| 02/24 | C4 THERAPEUTICS : Corporate Presentation – February 2022 | PU |
| 02/24 | C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights | GL |
| 02/24 | C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 202.. | CI |
| 02/09 | Wells Fargo Starts C4 Therapeutics at Equalweight With $25 Price Target | MT |
| 01/21 | C4 THERAPEUTICS : Financial Statements - Form 8-K/A | PU |
| 01/21 | C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A) | AQ |
| 01/10 | C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb | MT |
| 01/10 | TRANSCRIPT : C4 Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference,.. | CI |
| 01/10 | C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po.. | PU |
| 01/10 | C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl.. | AQ |
| 01/10 | C4 THERAPEUTICS : Corporate Presentation – January 2022 | PU |
| 01/10 | C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P.. | GL |
| 01/10 | C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P.. | CI |
| 01/03 | C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference | GL |
| 2021 | C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation | PU |
| 2021 | C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) added to NASDAQ Biotechnology Index | CI |
| 2021 | C4 Therapeutics to Join NASDAQ Biotechnology Index | MT |
| 2021 | C4 Therapeutics Added to NASDAQ Biotechnology Index | GL |
| 2021 | C4 THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct F.. | AQ |
| 2021 | BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target | MT |
| 2021 | C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res.. | PU |
| 2021 | C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and .. | AQ |
| 2021 | C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Res.. | GL |
| 2021 | BRD9 TPD Summit Presentation | PU |
| 2021 | CFT8919 TPD Summit Presentation | PU |
| 2021 | C4 THERAPEUTICS : SVB Leerink Starts C4 Therapeutics at Outperform with $67 Price Target | MT |
| 2021 | INSIDER SELL : C4 Therapeutics | MT |
| 2021 | C4 THERAPEUTICS : Stifel Starts C4 Therapeutics at Hold With $45 Price Target | MT |
| 2021 | INSIDER SELL : C4 Therapeutics | MT |
| 2021 | INSIDER SELL : C4 Therapeutics | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
